Software to automatically calculate Response Evaluation Criteria in Solid
Tumors (RECSIT) and assess a patient's response to cancer treatment.
- Provides the automated evaluation of response to cancer treatment.
- Enables a more consistent assessment than current methods.
- User-friendly data input format.
RECSIT criteria are utilized in evaluating a cancer patient's condition in
clinical trials. There are nearly 3,000 clinical trials for new cancer therapies
currently on-going in the US alone, and even more across the rest of the world.
All of these trials involve a multitude of clinical researchers and massive
amounts of data to manipulate, organize and store. In 2011 alone, there have
been 1.6 million new cancer diagnoses, and a software solution that could be
used to monitor progress in all of these cancer patients in a more automated
fashion would be valuable.
RECSIT is a widely used set of guidelines to measure a patient's response to
cancer treatment. These criteria were set by an international collaboration
including the National Cancer Institutes of the US, Canada and the European
Organization for Research and Treatment of Cancer. Today, nearly all clinical
trials utilize these guidelines to assess response of solid tumors to treatment.
Emory researchers have developed an Automated RECSIT Calculator (ARC) into which
a patient's data are entered. A RECSIT score is automatically calculated,
labeling a patient with one of four outcomes: complete response, partial
response, stable disease or progressive disease. This software enables
consistent assessment of patient outcomes across all clinical trials, and
improves the ease of tracking those results.
The software tool has been created and is currently in use at Emory.